Onconova expands enrollment in Phase III INSPIRE trial of rigosertib in MDS

Onconova Therapeutics Inc. (NASDAQ:ONTX) said it will expand enrollment in the Phase III INSPIRE trial of IV rigosertib (Estybon, SyB L-1101, ON 01910.Na) to treat higher-risk myelodysplastic syndrome (MDS) in patients who progressed

Read the full 338 word article

User Sign In